
By modifying the bacterium Listeria monocytogenes, researchers are developing a promising vaccine against colorectal cancer.
Image Credit: CDC
Scientific Frontline: Extended "At a Glance" Summary: Oral Listeria-Based Colorectal Cancer Vaccine
The Core Concept: A novel oral vaccine utilizing a modified, highly attenuated strain of the bacterium Listeria monocytogenes to prime the immune system within the gastrointestinal tract and generate a targeted anti-tumor response.
Key Distinction/Mechanism: Unlike previous Listeria-based vaccines that require intravenous administration, this method employs oral delivery to directly target the gut tissue where colorectal cancer originates. By keeping the immune response localized, it generates tumor-specific CD8 T cells without causing listeriosis, spreading to other organs, or damaging healthy off-target tissue.
Origin/History: The research was led by Stony Brook University immunologist Brian Sheridan in collaboration with Cold Spring Harbor Laboratory. The findings were published in the Journal for the ImmunoTherapy of Cancer and announced in February 2026.
Major Frameworks/Components:
- Genetic Attenuation: Removal of key virulence genes from Listeria monocytogenes to ensure safe access to the intestinal immune system without causing systemic infection.
- Localized CD8 T Cell Response: Induction and accumulation of specialized, tumor-specific immune cells that remain stationed in the gut to provide immediate and long-lasting tumor protection.
- Combination Therapy Synergy: Coupling the oral immunization with existing immune checkpoint inhibitors to successfully "turn on" the immune system against tumors that were previously resistant to standard immunotherapy.

.jpg)

.jpg)



.jpg)


.jpg)






.jpg)
